What is the catalog number for Tenapanor (Butylene-d8)?

The catalog number for Tenapanor (Butylene-d8) is CS-T-97605.

What sizes are available for Tenapanor (Butylene-d8)?

Tenapanor (Butylene-d8) is available in the following size(s): 1 Each.

Is Tenapanor (Butylene-d8) in stock?

Tenapanor (Butylene-d8) is currently made to order / not held in immediate stock. Contact us for lead time.

Where can I find the safety data sheet (SDS/MSDS) for Tenapanor (Butylene-d8)?

The safety data sheet for Tenapanor (Butylene-d8) is available here: https://msds_v1.clearsynth.com/msds.asp?catnumber=CS-T-97605.

Tenapanor (Butylene-d8)

Tenapanor (Butylene-d8) is listed under Metabolite and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Tenapanor. The product is supplied by Clearsynth under CAT No. CS-T-97605. Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.

Product Specifications

Overview

"17-[[[3-[ (4S) -6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[ (4S) -6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide-d8 (deuterium labeled) is an inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), which is a major absorptive sodium transporter. It has therapeutic potential for lowering gastrointestinal sodium absorption and improving fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD."

Synonyms

Tenapanor (Butylene-d8)

Molecular Formula

C 50 H 58 D 8 Cl 4 N 8 O 10 S 2

Molecular Weight

1153.1

Additionnal Information

Tenapanor (Butylene-d8) is supplied with detailed characterization data compliant with regulatory guideline. Tenapanor (Butylene-d8) can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Tenapanor.

Storage Conditions

Refer MSDS for complete information.

Applications Notes

"17-[[[3-[ (4S) -6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[ (4S) -6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide-d8 (deuterium labeled) is an inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), which is a major absorptive sodium transporter. It has therapeutic potential for lowering gastrointestinal sodium absorption and improving fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD."